Key Highlights

  • The investigator-sponsored trial was conducted at Memorial Sloan Kettering Cancer Center.
  • Leadership team, including Interim CEO Richard Kender, highlighted the findings on the company’s website.
  • SER-155 aims to address a key side effect of cancer immunotherapy treatments.

The update, posted to the company’s website on July 8, 2026, marks a potential step forward in addressing a common and debilitating side effect of cancer immunotherapies.

What Happened

Seres Therapeutics shared findings from an investigator-sponsored trial of SER-155, conducted at Memorial Sloan Kettering Cancer Center. The company’s leadership, including Interim CEO Richard Kender and Chief Scientific Officer Dr. Matthew Henn, outlined the results without disclosing specific efficacy or safety metrics.

Why It Matters

Immune checkpoint inhibitors have transformed cancer care but often trigger severe gastrointestinal side effects, including enterocolitis. SER-155’s development could expand treatment options for patients experiencing these complications, potentially improving adherence to immunotherapy regimens. The trial’s progress may also signal broader opportunities in microbiome-based supportive care for oncology.

Market Context

Seres Therapeutics operates in the competitive microbiome therapeutics space, where companies are racing to develop treatments for conditions linked to gut bacteria imbalances. While the field has seen setbacks, including failed trials, successful outcomes could unlock significant market potential. Investors are closely watching SER-155’s ability to address unmet needs in cancer supportive care.

What's Next

The company has not disclosed next steps for SER-155, but further clinical development or partnerships could follow. Analysts from Canaccord Genuity and H.C. Wainwright may weigh in on the trial’s implications for Seres’ pipeline.

Additional data or regulatory discussions could shape the therapy’s path toward commercialization.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.